ScoreWhy is Aclaris Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -5.82% of over the last 5 years
2
With a fall in Net Profit of -44.11%, the company declared Very Negative results in Sep 25
- NET SALES(Q) At USD 3.3 MM has Fallen at -21.4%
- ROCE(HY) Lowest at -113.23%
- RAW MATERIAL COST(Y) Grown by 43.18% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 94.12%, its profits have fallen by -14.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Aclaris Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aclaris Therapeutics, Inc.
111.18%
2.12
99.64%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.27%
EBIT Growth (5y)
-5.82%
EBIT to Interest (avg)
-71.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.89%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.76
EV to EBIT
-5.42
EV to EBITDA
-5.48
EV to Capital Employed
14.39
EV to Sales
22.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-265.41%
ROE (Latest)
-44.94%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
NET PROFIT(HY)
Higher at USD -28.44 MM
-25What is not working for the Company
NET SALES(Q)
At USD 3.3 MM has Fallen at -21.4%
ROCE(HY)
Lowest at -113.23%
RAW MATERIAL COST(Y)
Grown by 43.18% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 6.27 times
PRE-TAX PROFIT(Q)
At USD -14.51 MM has Fallen at -25.61%
NET PROFIT(Q)
At USD -14.51 MM has Fallen at -25.61%
Here's what is not working for Aclaris Therapeutics, Inc.
Net Sales
At USD 3.3 MM has Fallen at -21.4%
over average net sales of the previous four periods of USD 4.2 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -14.51 MM has Fallen at -25.61%
over average net sales of the previous four periods of USD -11.56 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -14.51 MM has Fallen at -25.61%
over average net sales of the previous four periods of USD -11.56 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Debtors Turnover Ratio
Lowest at 6.27 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 43.18% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
